share_log

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals | 8-K：NeuroBo Pharmaceuticals評估用於治療肥胖的DA-1726的1期臨床試驗首次獲得IRB批准
SEC announcement ·  02/29 21:33

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。